Clinical trials: SARS CoV 2 Infection
Covid19
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19.
- Trial name
- NCT04913675
- Testing
- sotrovimab
- Where
- 50 sites in United States, France and 1 more
- Volunteers
- 1,065 people
- Sponsor
- Vir Biotechnology, Inc.
COVID-19, SARS-CoV-2 Infection
Safety and Immunogenicity of NVX-CoV2705
This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120…
- Trial name
- COVID-19 (NCT07079670)
- Testing
- NVX-CoV2705
- Where
- 10 sites in United States
- Volunteers
- 676 people, healthy volunteers welcome
- Sponsor
- Sanofi
COVID-19
Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers
This is a Phase 1/2a clinical trial to assess the safety and immunogenicity of AdCLD-CoV19 in healthy adults.
- Trial name
- NCT04666012
- Testing
- AdCLD-CoV19
- Where
- 5 sites in South Korea
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Cellid Co., Ltd.
Covid
Covid-19 Data Analyses in Brazil
This descriptive study aims to describe the Brazilian scenario of patients hospitalized due to COVID-19 and to analyze the impact of COVID-19 on the Brazilian public health system.
- Trial name
- BRAVO (NCT06652451)
- Where
- Brazil
- Volunteers
- 361,000 people
- Sponsor
- AstraZeneca
Covid19
Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19
This is a 2 part study where the first part (Phase 1) evaluates the safety of XVR011 and aims to identify the recommended Phase 2 dose.
- Trial name
- NCT04884295
- Testing
- XVR011
- Where
- 6 sites in Belgium, Italy and 1 more
- Volunteers
- 27 people
- Sponsor
- ExeVir Bio BV
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345…
- Conditions
- SARS-CoV-2, Influenza, RSV
- Trial name
- NCT05585632
- Testing
- mRNA-1010, mRNA-1345, mRNA-1273.214
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus…
- Trial name
- NCT05119855
- Testing
- 9vHPV Vaccine, mRNA-1273 Vaccine
- Where
- 38 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19 Infection
CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19
This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5 days of treatment of participants with positive COVID-19 and at least one symptom of COVI019 in an out-patient setting.
- Trial name
- CRISIS2 (NCT04575038)
- Testing
- Brequinar
- Where
- 14 sites in United States
- Volunteers
- 115 people
- Sponsor
- Clear Creek Bio, Inc.
COVID-19, Infectious Disease
A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine
The goal of this clinical trial is to learn about, test, and compare JCXH-221 in healthy volunteers. The main aims to answer are: To assess the safety and tolerability of the JCXH-221 vaccine in healthy adult subjects To identify…
- Trial name
- NCT05743335
- Testing
- JCXH-221
- Where
- 4 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Immorna Biotherapeutics, Inc.
Covid19
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
The primary objective of this study is to evaluate the efficacy of BGB-DXP593 administered intravenously as a single dose in participants with mild to moderate COVID-19
- Trial name
- NCT04551898
- Testing
- BGB-DXP593
- Where
- 18 sites in United States, Brazil and 2 more
- Volunteers
- 181 people
- Sponsor
- BeiGene
Covid19
Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients
The current study will investigate the tolerability and efficacy of inhaled Carragelose® versus saline in hospitalized COVID-19 patients.
- Trial name
- NCT04793984
- Testing
- Carragelose, NaCl
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- Marinomed Biotech AG
COVID-19 Respiratory Infection
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled HH-120 Aerosol in Healthy Volunteers
This is a Phase 1, randomized, double-blinded, placebo controlled, dose escalation study of HH-120 in healthy adult volunteers. HH-120 is a novel inhalable biologic being developed for COVID-19 treatment.
- Trial name
- NCT05116865
- Testing
- HH-120 Dose 1, HH-120 Dose 2, HH-120 Dose 3
- Where
- Australia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Huahui Health
COVID-19
Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above
This trial adopts a randomized, double-blind and positive control design, it is planned to recruit 1800 healthy participants who have been vaccinated with 2/3 doses of COVID-19 inactivated vaccine or mRNA vaccine for 3 months.
- Trial name
- COVID-19 (NCT05382871)
- Testing
- BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell), WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell), COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Hong Kong
- Volunteers
- 1,804 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Severe Acute Respiratory Syndrome
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
OSCAR (Otilimab in Severe COVID-19 Related Disease) is a multi-center, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of otilimab for the treatment of severe pulmonary COVID-19 related…
- Trial name
- OSCAR (NCT04376684)
- Testing
- Otilimab, Standard of care
- Where
- 120 sites in United States, Argentina and 17 more
- Volunteers
- 1,156 people
- Sponsor
- GlaxoSmithKline
Covid19, Hypoxemia
A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
Patients with COVID-19 frequently develop lower respiratory complications. Difficulty breathing and a low concentration of oxygen in the blood are of concern in patients with COVID-19, as they indicate that the lungs may be…
- Trial name
- NCT04771000
- Testing
- Ambrisentan
- Where
- 13 sites in Croatia, Spain
- Volunteers
- 88 people
- Sponsor
- Noorik Biopharmaceuticals AG
Covid19
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise
This is a Phase 2a randomized, placebo-controlled study designed to investigate the efficacy, safety and tolerability of COVI-MSC in treating post COVID-19 "long haul" pulmonary compromise.
- Trial name
- BR (NCT04992247)
- Testing
- COVI-MSC
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19
Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection
The purpose of the study is to confirm if BACTEK-R (MV130) provides clinical benefit in subject with mild pneumonia (CURB-65≤2) by COVID-19 admitted to the Hospital.
- Trial name
- NCT04363814
- Testing
- Bactek-R
- Where
- Dominican Republic
- Volunteers
- 100 people
- Sponsor
- Inmunotek S.L.
SARS-CoV-2, COVID-19 Vaccines
Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data
The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall…
- Trial name
- NCT06199934
- Testing
- Vaccination
- Where
- United States
- Volunteers
- 19,853,610 people
- Sponsor
- Pfizer
Coronavirus, Covid19
COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities
The primary objectives of this study are to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine CVnCoV, and to evaluate the humoral immune responses 14 days…
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04860258
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium
- Volunteers
- 129 people
- Sponsor
- CureVac
COVID-19 Pneumonia, Acute Respiratory Distress Syndrome
Respiratory COVID-19: A Randomized, Sham-Controlled Study
A study of intubated critically ill patients infected with SARS-COV-2 to evaluate the safety and treatment effects of ultraviolet-A (UVA) light administered by a novel device via endotracheal tube in a first-in-human study.
- Conditions
- COVID-19 Pneumonia, Acute Respiratory Distress Syndrome, COVID-19 Acute Respiratory Distress Syndrome, COVID-19 Respiratory Infection
- Trial name
- NCT05166915
- Testing
- UVA Light Emitting Catheter
- Where
- 2 sites in Spain
- Sponsor
- Aytu BioPharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.